Journal
DIABETES CARE
Volume 34, Issue 7, Pages 1497-1502Publisher
AMER DIABETES ASSOC
DOI: 10.2337/dc10-2386
Keywords
-
Categories
Funding
- Commonwealth Department of Health and Aged Care
- Abbott Australasia Pty Ltd.
- Alphapharm Pty Ltd.
- Aventis Pharmaceutical
- AstraZeneca
- Bristol-Myers Squibb Pharmaceuticals
- Eli Lilly (Australia) Pty Ltd.
- GlaxoSmithKline
- Janssen-Cilag (Australia) Pty Ltd.
- Merck Lipha s.a.
- Merck Sharp & Dohme (Australia)
- Novartis Pharmaceutical (Australia) Pty Ltd.
- Novo Nordisk Pharmaceutical Pty Ltd.
- Pharmacia and Upjohn Pty Ltd.
- Pfizer Pty Ltd.
- Roche Diagnostics
- Sanofi Synthelabo (Australia) Pty Ltd.
- Servier Laboratories (Australia) Pty Ltd.
- BioRad Laboratories Pty Ltd.
- HITECH Pathology Pty Ltd.
- Australian Kidney Foundation
- Diabetes Australia
- Diabetes Australia (Northern Territory)
- Queensland Health
- South Australian Department of Human Services
- Tasmanian Department of Health and Human Services
- Territory Health Services
- Victorian Department of Human Services
- Health Department of Western Australia
- National Health Medical Research Council (Australia) [1013538]
- Victorian Health Promotion Foundation
- National Health Medical Research Council
Ask authors/readers for more resources
OBJECTIVE-To investigate pedometer-measured physical activity (PA) in 2000 and change in PA over 5 years with subsequent risk of dysglycemia by 2005. RESEARCH DESIGN AND METHODS-This prospective cohort study in Tasmania, Australia, analyzed 458 adults with normal glucose tolerance and a mean (SD) age of 49.7 (12.1) years in 2000. Variables assessed in 2000 and 2005 included PA, by pedometer and questionnaire, nutrient intake, and other lifestyle factors. Incident dysglycemia was defined as the development of impaired fasting glucose or impaired glucose tolerance revealed by oral glucose tolerance testing in 2005, without type 2 diabetes. RESULTS-Incident dysglycemia developed in 26 participants during the 5-year period. Higher daily steps in 2000 were independently associated with a lower 5-year risk of incident dysglycemia (adjusted odds ratio [AOR] 0.87 [95% CI 0.77-0.97] per 1,000-step increment). Higher daily steps in 2005, after controlling for baseline steps in 2000 (thus reflecting change in steps over 5 years), were not associated with incident dysglycemia (AOR 1.02 [0.92-1.14]). Higher daily steps in 2000 were also associated with lower fasting blood glucose, but not 2-h plasma glucose by 2005. Further adjustment for BMI or waist circumference did not remove these associations. CONCLUSIONS-Among community-dwelling adults, a higher rate of daily steps is associated with a reduced risk of incident dysglycemia. This effect appears to be not fully mediated through reduced adiposity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available